These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18189345)

  • 1. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma.
    Ressom HW; Varghese RS; Goldman L; An Y; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Drake SK; Goldman R
    J Proteome Res; 2008 Feb; 7(2):603-10. PubMed ID: 18189345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of MALDI-TOF mass spectrometry data for detection of glycan biomarkers.
    Ressom HW; Varghese RS; Goldman L; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Goldman R
    Pac Symp Biocomput; 2008; ():216-27. PubMed ID: 18229688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated peptide and glycan biomarker discovery using MALDI-TOF mass spectrometry.
    Varghese RS; Goldman L; An Y; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Drake SK; Goldman R; Ressom HW
    Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():3791-4. PubMed ID: 19163537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of hepatocellular carcinoma using glycomic analysis.
    Goldman R; Ressom HW; Varghese RS; Goldman L; Bascug G; Loffredo CA; Abdel-Hamid M; Gouda I; Ezzat S; Kyselova Z; Mechref Y; Novotny MV
    Clin Cancer Res; 2009 Mar; 15(5):1808-13. PubMed ID: 19223512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of abnormal fucosylated-glycans recognized by LTL in saliva of HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Zhang J; Zhong Y; Zhang P; Du H; Shu J; Liu X; Zhang H; Guo Y; Jia Z; Niu L; Yang F; Li Z
    Glycobiology; 2019 Mar; 29(3):242-259. PubMed ID: 30535277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma.
    Orvisky E; Drake SK; Martin BM; Abdel-Hamid M; Ressom HW; Varghese RS; An Y; Saha D; Hortin GL; Loffredo CA; Goldman R
    Proteomics; 2006 May; 6(9):2895-902. PubMed ID: 16586431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of salivary N-glycome in HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Qin Y; Zhong Y; Ma T; Zhang J; Yang G; Guan F; Li Z; Li B
    Glycoconj J; 2017 Aug; 34(4):523-535. PubMed ID: 28389847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data.
    Tang Z; Varghese RS; Bekesova S; Loffredo CA; Hamid MA; Kyselova Z; Mechref Y; Novotny MV; Goldman R; Ressom HW
    J Proteome Res; 2010 Jan; 9(1):104-12. PubMed ID: 19764807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peak selection from MALDI-TOF mass spectra using ant colony optimization.
    Ressom HW; Varghese RS; Drake SK; Hortin GL; Abdel-Hamid M; Loffredo CA; Goldman R
    Bioinformatics; 2007 Mar; 23(5):619-26. PubMed ID: 17237065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis.
    Kam RK; Poon TC; Chan HL; Wong N; Hui AY; Sung JJ
    Clin Chem; 2007 Jul; 53(7):1254-63. PubMed ID: 17510303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
    Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis.
    Ying X; Han SX; Wang JL; Zhou X; Jin GH; Jin L; Wang H; Wu L; Zhang J; Zhu Q
    Diagn Pathol; 2013 Aug; 8():130. PubMed ID: 23915185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased concentrations of apo A-I and apo A-II fragments in the serum of patients with hepatocellular carcinoma by magnetic beads-assisted MALDI-TOF mass spectrometry.
    Liu Y; Sogawa K; Sunaga M; Umemura H; Satoh M; Kazami T; Yoshikawa M; Tomonaga T; Yokosuka O; Nomura F
    Am J Clin Pathol; 2014 Jan; 141(1):52-61. PubMed ID: 24343737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum.
    Goldman R; Ressom HW; Abdel-Hamid M; Goldman L; Wang A; Varghese RS; An Y; Loffredo CA; Drake SK; Eissa SA; Gouda I; Ezzat S; Moiseiwitsch FS
    Carcinogenesis; 2007 Oct; 28(10):2149-53. PubMed ID: 17724376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma with magnetic bead-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Liu T; Xue R; Huang X; Zhang D; Dong L; Wu H; Shen X
    Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):542-50. PubMed ID: 21659380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma.
    Tsai TH; Wang M; Di Poto C; Hu Y; Zhou S; Zhao Y; Varghese RS; Luo Y; Tadesse MG; Ziada DH; Desai CS; Shetty K; Mechref Y; Ressom HW
    J Proteome Res; 2014 Nov; 13(11):4859-68. PubMed ID: 25077556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis.
    He J; Zeng ZC; Xiang ZL; Yang P
    World J Gastroenterol; 2014 Mar; 20(11):3025-32. PubMed ID: 24659894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.